MedNest Incorporates and Launches PharmaNest
MedNest incorporates and launches PharmaNest as a wholly owned subsidiary. The mission of PharmaNest is to commercialize breakthrough international IND-Enabling Technologies and Services for the US Markets.
Online, July 24, 2011 (Newswire.com) - MedNest incorporates and launches PharmaNest as a wholly owned subsidiary. The mission of PharmaNest is to commercialize breakthrough international IND-Enabling Technologies and Services for the US Markets.
"An enabling technology is an invention or innovation, that can be applied to drive radical change in the capabilities of a user or culture. Enabling technologies are characterized by rapid development of subsequent derivative technologies, often in diverse fields. In the field of Drug discovery and Pharmaceutical Development, IND-enabling technologies are poised to accelerate the discovery of new therapeutic compounds and significantly reduce time to market and safety profiles" says Mathieu Petitjean, PhD, President of MedNest.
Innovative technologies and services have the potential to redefine the workflows, quality and cost structure of the efforts dedicated by pharmaceutical companies and biotechnology companies to more Drug candidates from a "lead" concept to an IND by disrupting conventional and generally accepted process to:
• Perform Animal Pharmacology and Toxicology Studies,
• Develop Compound Chemistry Technologies and Manufacturing processes
• Develop Clinical Protocols, with increased Investigator and Patient participation
• Create innovative ways to execute clinical trials while increasing the protection of the subject involved.
There is an increasing amount of innovative technologies around the world that have the potential to enable major improvements. But these technologies are often captive of their local ecosystems and markets. In addition, large distances and cultural gaps slow down their adoption. Most often, the absence of relevant leadership teams, at the right time, is the key reason why promising technologies do not harvest the success that they deserve. Pertinent and creative business model may be as well one of the manor root causes of failure. PharmaNest is poised to resolve these market entry barriers for the US markets.
PharmaNest already benefits from a remarkable track record of international clients and partners developed by MedNest, including Fluofarma, Creapharm, Disposable Lab, GemacBio, LLTECH, Atoxigen, ITEC Services among others.
International IND-Enabling Technology providers are invited to contact PharmaNest to explore opportunities for joint commercialization in the USA.